Business Description
Caribou Biosciences Inc
NAICS : 541713
SIC : 2833
ISIN : US1420381089
Description
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8.33 | |||||
| Equity-to-Asset | 0.8 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | -0.24 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 1.39 | |||||
| Beneish M-Score | -2.51 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 2.9 | |||||
| 3-Year EBITDA Growth Rate | -16.4 | |||||
| 3-Year EPS without NRI Growth Rate | -16.6 | |||||
| 3-Year FCF Growth Rate | -10.7 | |||||
| 3-Year Book Growth Rate | 163.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 69.19 | |||||
| 9-Day RSI | 60.41 | |||||
| 14-Day RSI | 55.88 | |||||
| 6-1 Month Momentum % | -56.61 | |||||
| 12-1 Month Momentum % | -51.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.84 | |||||
| Quick Ratio | 8.84 | |||||
| Cash Ratio | 8.43 | |||||
| Days Sales Outstanding | 15.06 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -30.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -794.21 | |||||
| Net Margin % | -737.81 | |||||
| ROE % | -33.39 | |||||
| ROA % | -27.27 | |||||
| ROIC % | -106.14 | |||||
| ROC (Joel Greenblatt) % | -343.38 | |||||
| ROCE % | -31.57 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 19.88 | |||||
| PB Ratio | 1.06 | |||||
| Price-to-Tangible-Book | 1.06 | |||||
| EV-to-EBIT | -0.8 | |||||
| EV-to-EBITDA | -0.81 | |||||
| EV-to-Revenue | 6.32 | |||||
| EV-to-Forward-Revenue | 5.46 | |||||
| EV-to-FCF | -0.88 | |||||
| Price-to-Net-Current-Asset-Value | 1.72 | |||||
| Price-to-Net-Cash | 1.84 | |||||
| Earnings Yield (Greenblatt) % | -125 |
Balance Sheet Breakdown
Cashflow Statement Breakdown
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CRBU
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Caribou Biosciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 14.689 | ||
| EPS (TTM) ($) | -1.78 | ||
| Beta | 0 | ||
| Volatility % | 82.42 | ||
| 14-Day RSI | 55.88 | ||
| 14-Day ATR ($) | 0.33261 | ||
| 20-Day SMA ($) | 4.465 | ||
| 12-1 Month Momentum % | -51.57 | ||
| 52-Week Range ($) | 4.05 - 13.19 | ||
| Shares Outstanding (Mil) | 61.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Caribou Biosciences Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Caribou Biosciences Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Caribou Biosciences Inc Frequently Asked Questions
What is Caribou Biosciences Inc(CRBU)'s stock price today?
The current price of CRBU is $4.79. The 52 week high of CRBU is $13.19 and 52 week low is $4.05.
When is next earnings date of Caribou Biosciences Inc(CRBU)?
The next earnings date of Caribou Biosciences Inc(CRBU) is 2023-08-09 Est..
Does Caribou Biosciences Inc(CRBU) pay dividends? If so, how much?
Caribou Biosciences Inc(CRBU) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers